Alnylam Pharmace. buy DropStone
Summary
This prediction ended on 06.01.21 with a price of €103.98. With a performance of -6.56%, the BUY prediction for Alnylam Pharmace. by DropStone closed slightly in the red. DropStone has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -3.982% | -3.982% | -27.680% | 17.508% |
iShares Core DAX® | -1.785% | -1.250% | 11.664% | 12.714% |
iShares Nasdaq 100 | -2.154% | 0.300% | 37.531% | 41.653% |
iShares Nikkei 225® | -4.028% | -3.746% | 17.142% | 0.393% |
iShares S&P 500 | -1.969% | 0.307% | 25.617% | 40.084% |
Comments by DropStone for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.